ReviewCancer immunology, immunotherapy : CII2010
Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy?
Review in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The Yin-Yang Dynamics in Cancer Pharmacogenomics and Personalized Medicine.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of itsIranian journal of basic medical sciences · 2018Article
- M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma.PloS one · 2018Article
- Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice.Archivum immunologiae et therapiae experimentalis · 2015Article
- Antitumor effects of recombinant antivascular protein ABRaA-VEGF121 combined with IL-12 gene therapy.Archivum immunologiae et therapiae experimentalis · 2014Article
- Tumor microenvironment and nanotherapeutics.Translational cancer research · 2013Article
- Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents.Gene therapy · 2013Article
- Evolving models of tumor origin and progression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer initiation and progression is strongly influenced by the tumor microenvironment consisting of various types of host cells (inflammatory cells, vascular cells and fibroblasts), extracellular matrix and non-matrix molecules. Host cells play a defining role in two major processes crucial for tumor growth: angiogenesis and escape from immune surveillance. The interdependence of these processes resemble the principles of Yin and Yang, as the stimulation of tumor angiogenesis inhibits effective immune responses, while angiogenesis inhibition may have the opposite effect. These considerations may be useful in developing anticancer strategies based on the potentially synergistic combinations of antiangiogenic and immunostimulatory drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.